Associated Papers
The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
Rudin S et al.
Genomics, Proteomics & Bioinformatics, 2017
Germline oncopharmacogenetics, a promising field in cancer therapy.
Pesenti C et al.
Cellular Oncology (dordrecht, Netherlands), 2015
Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
Dulucq S et al.
Expert Opinion on Drug Metabolism & Toxicology, 2014
The genetic architecture of methotrexate toxicity is similar in Drosophila melanogaster and humans.
Kislukhin G et al.
G3 (bethesda, Md.), 2013
23733889 (PubMed )
Supplement: supp_g3.113.006619_006619SI.pdf
Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.
Cecchin E et al.
The Pharmacogenomics Journal, 2011
Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.
Rocha V et al.
Leukemia, 2009
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Toffoli G et al.
Journal of Chemotherapy (florence, Italy), 2004
Select a paper to view details